Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1744125Generated: November 2, 2026

Monobasic potassium phosphate → methyl N-(4-{4-[4-(tert-butoxycarbonyl)piperazin-1-yl]phenyl}-1,2,5-oxadiazol-3-yl)leucinate

https://huagongshe.com/reaction/1744125

Reaction equation

Participants

RoleNameHCIDCharge
ReactantMonobasic potassium phosphateHCID 516951—
Reactantmethyl N-(4-{4-[4-(tert-butoxycarbonyl)piperazin-1-yl]phenyl}-1,2,5-oxadiazol-3-yl)-N-[(2,2,2-trichloroethoxy)carbonyl]leucinateHCID 69152043—
CatalystZincHCID 23994—
SolventTetrahydrofuranHCID 8028—
Productmethyl N-(4-{4-[4-(tert-butoxycarbonyl)piperazin-1-yl]phenyl}-1,2,5-oxadiazol-3-yl)leucinateHCID 69151159—

Reaction Steps

To methyl N-(4-{4-[4-(tert-butoxycarbonyl)piperazin-1-yl]phenyl}-1,2,5-oxadiazol-3-yl)-N-[(2,2,2-trichloroethoxy)carbonyl]leucinate (605 mg, 0.932 mmol) in THF (20 mL) was added activated zinc powder (610 mg, 9.32 mmol) and an aqueous solution of KH2PO4 (1.0 M, 1.8 mL, 1.8 mmol) dropwise. After 15 min an additional aliquot of aqueous KH2PO4 solution was added (1.0 M, 1.8 mL, 1.8 mmol) and the reaction mixture was stirred for 4 hours. The zinc powder was filtered off, rinsed with Et2O and water and the product extracted with ether (2×), dried over Na2SO4, concentrated in vacuo and purified by flash chromatography over silica gel (EtOAc/Hex, 25/5) to afford methyl N-(4-{4-[4-(tert-butoxycarbonyl)piperazin-1-yl]phenyl}-1,2,5-oxadiazol-3-yl)leucinate.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS07012075B2
Source datasetuspto-grants-2006_03
ORD IDord-9708e89992a046459bba3c9c4d3b6f8e
Source noteuspto-grants-2006_03